357 related articles for article (PubMed ID: 22034431)
1. Chemoenzymatic synthesis of homogeneous ultralow molecular weight heparins.
Xu Y; Masuko S; Takieddin M; Xu H; Liu R; Jing J; Mousa SA; Linhardt RJ; Liu J
Science; 2011 Oct; 334(6055):498-501. PubMed ID: 22034431
[TBL] [Abstract][Full Text] [Related]
2. Chemoenzymatic synthesis of ultralow and low-molecular weight heparins.
Wang T; Liu L; Voglmeir J
Biochim Biophys Acta Proteins Proteom; 2020 Feb; 1868(2):140301. PubMed ID: 31678194
[TBL] [Abstract][Full Text] [Related]
3. Chemoenzymatic synthesis of the next generation of ultralow MW heparin therapeutics.
Masuko S; Linhardt RJ
Future Med Chem; 2012 Mar; 4(3):289-96. PubMed ID: 22393937
[TBL] [Abstract][Full Text] [Related]
4. De novo synthesis of a narrow size distribution low-molecular-weight heparin.
Chandarajoti K; Xu Y; Sparkenbaugh E; Key NS; Pawlinski R; Liu J
Glycobiology; 2014 May; 24(5):476-86. PubMed ID: 24626379
[TBL] [Abstract][Full Text] [Related]
5. Homogeneous low-molecular-weight heparins with reversible anticoagulant activity.
Xu Y; Cai C; Chandarajoti K; Hsieh PH; Li L; Pham TQ; Sparkenbaugh EM; Sheng J; Key NS; Pawlinski R; Harris EN; Linhardt RJ; Liu J
Nat Chem Biol; 2014 Apr; 10(4):248-50. PubMed ID: 24561662
[TBL] [Abstract][Full Text] [Related]
6. Preparation and application of a 'clickable' acceptor for enzymatic synthesis of heparin oligosaccharides.
Cai C; Edgar K; Liu J; Linhardt RJ
Carbohydr Res; 2013 May; 372():30-4. PubMed ID: 23524108
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological effects and clinical applications of ultra low molecular weight heparins.
Liu Z; Ji S; Sheng J; Wang F
Drug Discov Ther; 2014 Feb; 8(1):1-10. PubMed ID: 24647152
[TBL] [Abstract][Full Text] [Related]
8. Chemical synthesis and pharmacological properties of heparin pentasaccharide analogues.
Zhou Z; Zhang L; Wu X; Luo L; Wu J; Xu D; Wu M
Eur J Med Chem; 2022 Apr; 234():114256. PubMed ID: 35279609
[TBL] [Abstract][Full Text] [Related]
9. Differential metastasis inhibition by clinically relevant levels of heparins--correlation with selectin inhibition, not antithrombotic activity.
Stevenson JL; Choi SH; Varki A
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):7003-11. PubMed ID: 16203794
[TBL] [Abstract][Full Text] [Related]
10. The design and synthesis of new synthetic low-molecular-weight heparins.
Chandarajoti K; Liu J; Pawlinski R
J Thromb Haemost; 2016 Jun; 14(6):1135-45. PubMed ID: 26990516
[TBL] [Abstract][Full Text] [Related]
11. Complete mass spectral characterization of a synthetic ultralow-molecular-weight heparin using collision-induced dissociation.
Kailemia MJ; Li L; Ly M; Linhardt RJ; Amster IJ
Anal Chem; 2012 Jul; 84(13):5475-8. PubMed ID: 22715938
[TBL] [Abstract][Full Text] [Related]
12. Molecular weight determines the frequency of delayed type hypersensitivity reactions to heparin and synthetic oligosaccharides.
Ludwig RJ; Schindewolf M; Alban S; Kaufmann R; Lindhoff-Last E; Boehncke WH
Thromb Haemost; 2005 Dec; 94(6):1265-9. PubMed ID: 16411404
[TBL] [Abstract][Full Text] [Related]
13. Rational design of anticoagulant drugs using oligosaccharide chemistry.
El Hadri A; Petitou M
Chimia (Aarau); 2011; 65(1-2):14-7. PubMed ID: 21469438
[TBL] [Abstract][Full Text] [Related]
14. Extended Physicochemical Characterization of the Synthetic Anticoagulant Pentasaccharide Fondaparinux Sodium by Quantitative NMR and Single Crystal X-ray Analysis.
Wildt W; Kooijman H; Funke C; Üstün B; Leika A; Lunenburg M; Kaspersen F; Kellenbach E
Molecules; 2017 Aug; 22(8):. PubMed ID: 28817073
[TBL] [Abstract][Full Text] [Related]
15. [Is there a difference between low-molecular-weight heparins?].
Eritsland J
Tidsskr Nor Laegeforen; 2005 Oct; 125(20):2802-3. PubMed ID: 16244685
[TBL] [Abstract][Full Text] [Related]
16. Chemoenzymatic Synthesis of Glycosaminoglycans.
Zhang X; Lin L; Huang H; Linhardt RJ
Acc Chem Res; 2020 Feb; 53(2):335-346. PubMed ID: 31714740
[TBL] [Abstract][Full Text] [Related]
17. Facile chemoenzymatic synthesis of unmodified anticoagulant ultra-low molecular weight heparin.
Zhang G; Yang K; Wang L; Cheng Y; Liu C
Org Biomol Chem; 2022 Nov; 20(42):8323-8330. PubMed ID: 36239281
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of allergic late airway responses by inhaled heparin-derived oligosaccharides.
Ahmed T; Ungo J; Zhou M; Campo C
J Appl Physiol (1985); 2000 May; 88(5):1721-9. PubMed ID: 10797135
[TBL] [Abstract][Full Text] [Related]
19. Monitoring of heparin and its low-molecular-weight analogs by silicon field effect.
Milovic NM; Behr JR; Godin M; Hou CS; Payer KR; Chandrasekaran A; Russo PR; Sasisekharan R; Manalis SR
Proc Natl Acad Sci U S A; 2006 Sep; 103(36):13374-9. PubMed ID: 16938875
[TBL] [Abstract][Full Text] [Related]
20. Production method affects the pharmacokinetic and ex vivo biological properties of low molecular weight heparins.
Brieger D; Dawes J
Thromb Haemost; 1997 Feb; 77(2):317-22. PubMed ID: 9157589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
